The aim of this non-interventional study (NIS) is to assess, under real-life conditions, woman's satisfaction with Levonogestrel IntraUterine System (LNG-IUS) in a young (18-30 years old (y.o.)) Spanish population taking into account their parity status.

Furthermore, the study is aimed to evaluate the impact of: menstrual bleeding pattern and satisfaction with it at baseline, LNG-IUS chosen, previously used contraceptive method and reasons for change to/ choice of a LNG-IUS on overall satisfaction with LNG-IUS use.

Inclusion Criteria:

• Women in childbearing age, between 18-30 years old.
• Women who have chosen a LNG-IUS as contraceptive method, after been adequately counselled by the physician about all contraceptive possible options.
• Women who have chosen a LNG-IUS mainly for contraceptive reasons, not due to heavy menstrual bleeding.
• Women with no desire to conceive for at least within the next 12 months.
• Women capable of reading and writing

Exclusion Criteria:

• Women whose main reason to use a LNG-IUS is not a contraceptive reason.
• Women with contraindication for LNG-IUS.
• Women with previous experience with a IUS.
• Women who have been diagnosed with heavy menstrual bleeding.
• Women with degenerative or other kind of diseases that could directly negatively impact their daily life.
• Women who have undergone a hysterectomy or irreversible contraceptive method.
• Women participating in a clinical trial.
• Women with a mental illness and unable to make decisions and follow instructions.
• Women with amenorrhea
• Women with clinical history of severe dysmenorrhea
• Women with concomitant medication that may lead changes in bleeding pattern (e.g. antiplatelets and/or anticoagulants)

Participants will be women in childbearing age between ≥18 to 30 years, who have freely chosen a LNG-IUS for contraception after being adequately counselled and informed of all contraceptive options by their physician at a routine visit prior to the first study visit (enrolment) in a routine clinical practice setting. Then, women eligible for the enrolment will be visiting the physician in a IUS insertion visit in a gynaecological clinical setting.

Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.